Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab

Mostrar otras versiones (1)

BACKGROUND: Modulation of the immune system to prevent lung injury is being widely used against the new coronavirus disease (COVID-19). The primary endpoint was mortality at 7 days after tocilizumab administration. Secondary endpoints were admission to the intensive care unit, development of ARDS an...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Montalvá, Adrián, Sellarés-Nadal, Júlia, Espinosa-Pereiro, Juan, Fernández-Hidalgo, Nuria, Pérez-Hoyos, Santiago, Salvador, Fernando, Durà, Xavier, Miarons, Marta, Antón, Andrés, Eremiev-Eremiev, Simeón, Sempere-González, Abiu, Monforte-Pallarés, Arnau, Bosch-Nicolau, Pau, Augustin, Salvador, Sampol, Júlia, Guillén-del-Castillo, Alfredo, Almirante, Benito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier España, S.L.U. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213005/
https://www.ncbi.nlm.nih.gov/pubmed/35755602
http://dx.doi.org/10.1016/j.medcle.2021.06.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213005/
https://www.ncbi.nlm.nih.gov/pubmed/35755602
http://dx.doi.org/10.1016/j.medcle.2021.06.023

Ejemplares similares